catechin has been researched along with Proteinuria in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, G; Zhang, J | 1 |
| Feng, C; Guo, L; Jin, H; Li, Y; Yang, X | 1 |
| Bailón, E; Delpón, E; Duarte, J; Galindo, P; Gómez-Guzmán, M; Jiménez, R; Lopez-Sepulveda, R; O'Valle, F; Perez-Vizcaino, F; Quintela, AM; Romero, M; Sánchez, M; Zarzuelo, MJ | 1 |
| Duarte, J; Galindo, P; Gómez-Guzmán, M; Jiménez, R; López-Sepúlveda, R; Pérez-Vizcaíno, F; Quintela, AM; Romero, M; Sánchez, M; Tamargo, J; Vargas, F; Zarzuelo, MJ | 1 |
| Cho, EJ; Rhyu, DY; Yokozawa, T | 1 |
| Kim, M; Oya, T; Yamabe, N; Yokozawa, T | 1 |
6 other study(ies) available for catechin and Proteinuria
| Article | Year |
|---|---|
Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats.
Topics: Administration, Oral; Animals; Biological Availability; Calorimetry, Differential Scanning; Catechin; Crystallography, X-Ray; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Hydrogen-Ion Concentration; Kidney; Microscopy, Electron, Transmission; Nanoparticles; Nephrotic Syndrome; Polymers; Powder Diffraction; Proteinuria; Rats, Sprague-Dawley; Renal Agents; Solubility | 2018 |
[In vivo study of the renoprotective effects of EGCG in diabetic db/db mice].
Topics: Angiotensin II; Animals; Catechin; Diabetes Mellitus; Kidney; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 3; NADPH Oxidases; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proteinuria; Proto-Oncogene Proteins c-akt | 2016 |
Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats.
Topics: Animals; Atherosclerosis; Blood Pressure; Catechin; Cyclooxygenase 2; Endothelium, Vascular; Hypertension; Hypertrophy; Inflammation; Inflammation Mediators; Kidney; Male; MAP Kinase Signaling System; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Phosphorylation; Phytotherapy; Plant Extracts; Prostaglandins; Proteinuria; Rats; Rats, Wistar; Up-Regulation; Vascular Diseases; Vasoconstriction | 2011 |
Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension.
Topics: Animals; Aorta; Blood Pressure; Catechin; Desoxycorticosterone; Dinoprost; Endothelin-1; Endothelium, Vascular; Hypertension; Male; Malondialdehyde; NADPH Oxidases; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Oxidative Stress; Proteinuria; Rats; Rats, Wistar; Sodium Chloride, Dietary; Superoxides | 2012 |
(-)-Epicatechin 3-O-gallate ameliorates the damages related to peroxynitrite production by mechanisms distinct from those of other free radical inhibitors.
Topics: Animals; Azoles; Blood Urea Nitrogen; Catechin; Copper; Creatinine; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Isoindoles; Japan; Kidney; Lipopolysaccharides; Lysine; Male; Nitric Oxide; Organoselenium Compounds; Peroxidase; Phytotherapy; Plant Extracts; Plant Roots; Proteinuria; Rats; Rats, Wistar; Reperfusion Injury; Rheum; Superoxide Dismutase; Tyrosine; Uric Acid; Zinc | 2004 |
Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats.
Topics: Animals; Body Weight; Catechin; Cyclooxygenase 2; Diabetic Nephropathies; Fibronectins; Kidney; Male; NF-kappa B; Nitric Oxide Synthase Type II; Organ Size; Proteinuria; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Transforming Growth Factor beta | 2006 |